Next Phase Newsletter

A large pharmaceutical company based in the US is looking to make strategic investments in therapeutic assets.  The firm uses a variety of partnership structures on a case by case basis, but typically focuses on acquiring or in-licensing assets.  The firm is interested in partnering with biotech companies worldwide.

The firm’s partnering is currently focused on oncology (including both solid tumors and liquid tumors), liver diseases (particularly NASH and fibrosis), inflammatory diseases, and cures for infectious disease (particularly cures for hepatitis B and HIV; vaccines will also be considered). The firm is interested in both small molecule and biologic technologies, but is generally not interested in cell therapies.

While the firm may consider assets at any stage, the firm typically works with companies at the late phase I-early phase II stage, and in the oncology field prefers that companies have some human proof of concept data. Partnerships in the infectious disease field may be formed at an earlier stage, prior to human clinical trials.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A large Chinese conglomerate with approximately USD 50 billion AUM makes direct investments into early stage healthcare IT space via a specialized corporate VC fund. The fund can invest anywhere from US$ 1 million up to $50 million, depending on the deal. Operating from its headquarter in Shanghai, China with an additional office in San Francisco, the firm is currently seeking opportunities in China and the United States.

Within healthcare IT, the firm focuses on consumer-facing mobile and internet companies with large market potential. Examples include telemedicine and patient-doctor interface than lower healthcare costs; data and specimen management systems that improves healthcare workflow; and consumer-oriented biomarker and molecular diagnostic tools. The firm is interested in technologies that can be applied to the Chinese market; however this is not a requirement for investment.

For overseas opportunities, the firm is interested in highly reputable management teams with strong record of success. The firm typically acts as lead investor in a financing round and seeks a board seat after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the western United States is currently seeking new investment in the healthcare space. The firm has manages approximately $4 billion in total assets and the current venture fund size is $325million. The firm seeks to invest in companies targeting those sectors: consumer applications and services, enterprise infrastructure and apps, and big-bet disruptive technologies. The firm invests in companies in various stages, however it generally invests in venture rounds. The typical investment size ranges from $5 million to $10million.The firm looks to be a lead investor and also co-invests with others for large investments. The firm seeks to invest in companies based in the US.

In the life sciences, the firm is seeking to invest in the healthcare IT, m-Health, diagnostics and selective medical device companies. The firm is not interested in drug development companies. For healthcare IT, the firm invests in companies developing software, solutions and analytical platforms targeting pharma, healthcare providers and consumers. For diagnostics, the firm prefers to invest in genomics and low-risk diagnostic devices. For devices, the firm considers companies with a clear regulatory pathway. In terms of stage of development, the firm focuses on investments in series A round, but it also invests in seed and growth stages, depending on the opportunity. Historically, the firm was active in companies developing drug discovery platform, gene sequencing equipment, synthetic biology, human gene-phenotype database and blood-testing platforms.

The firm invests in privately held life science companies with experienced management teams and innovative technologies. The firm looks to take a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm that was founded in 2008 based in Europe with an additional office in New York City manages €176 million in total assets across two funds. The firm recently held a first close of its second fund at €103 million. The firm typically makes equity investment into early-stage life science companies. The typical investment size ranges from €0.5million-€7million ($0.7million-$10million). The second fund looks to make 10 to 15 investments. The firm generally invests in companies based in the US and Europe.

The venture capital firm is currently looking for new investment opportunities in the life science space. The firm focuses on Therapeutics, Diagnostics and Medical Devices sectors. The firm is very opportunistic in terms of subsectors and indications, and it is most interested in companies in pre-clinical and clinical stages. In the past, the firm was active in therapeutic and diagnostic companies developing drug delivery and gene therapy technologies. The firm was also active in device companies developing single use devices and non-active implantable devices.

The firm primarily invests in private companies with experienced management teams, but it will also consider public companies, depending on the opportunity. The firm seeks to take a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A 100-member angel network based in the USA has invested over $60 million in almost 200 deals.  The group considers early stage companies in a wide range of industry sectors including life sciences. The group can either lead or co-invest in a financing round from $25K to up to $500K per deal. Investments are made in convertible preferred equity or convertible notes depending on the deal. The group is seeking new opportunities across the US.

Within life sciences, the angel network is most interested in early stage medical device, diagnostic, and healthcare IT innovations. The group considers medical devices at all risk levels and is agnostic to disease indications. The group would also consider therapeutics, but with less interest as the development timeline and risks of early stage therapeutics are often not suitable for the group.

The angel network is looking for competent entrepreneurs with sector expertise. The group seeks active participation after investment and can help build the management team when needed. The group typically avoids crowdfunded investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A China-based healthcare-specific RMB fund has raised three funds to date and is now investing from its recently closed third fund. The firm is actively seeking to invest in early-growth and revenue-stage China-based companies, and also considers offshore companies that have significant operations in China or products that are strongly applicable to the Chinese market.

The firm is currently seeking companies in the healthcare service sector, which includes healthcare record management systems, healthcare IT, and mobile health. The firm is also interested in innovative medical devices that have large market potential. The firm is agnostic to therapeutic indications, but is not interested in large hospital equipment. The firm looks for companies that have “disruptive” technologies and/or products or business models that are game-changing. The firm prefers early-growth and revenue-stage companies, while it also invest in select early ventures that seek to establish critical infrastructures and platforms in the evolving Chinese healthcare industry.

The firm invests in entrepreneurs who have unique insights, exceptional domain knowledge and deep operational experience. In particular, the firm looks for management teams with successful track records in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The corporate VC arm of a large pharmaceutical company manages an evergreen fund with $400 million in assets under management. The firm looks to make investments generally in seed and Series A rounds with up to $10 million initially and up to $25 over the lifetime of the investment. The firm is open to reviewing opportunities from all around the globe.

The firm is currently interested in companies operating in sectors of therapeutics, diagnostics, medical devices and healthcare IT. The firm is fairly open to all types of technologies within these sectors pending that it be truly novel. The firm is not interested in pure reformulations or repurposing plays, and a higher level of interested in the cell and gene therapy spaces. For therapeutics the firm generally looks for companies in either pre-clinical or phase I of clinical development and for devices and diagnostics the firm will generally considers those that are in the clinical or already on the market. Only in cases of drug delivery devices would the firm look early than the clinical stage for devices. The firm is also open to technologies in all indication areas but generally only consider technologies targeting crowded spaces such as diabetes and Alzheimer’s if they are truly disruptive.

The firm is looking for privately held companies with experienced management teams and always look to take a board seat following investment. From time to time members of the firm have acted as management within portfolio companies as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.